The Place of Topical Combined Multicomponent Drugs in the Therapy of Complicated Dermatoses (Resolution of the Expert Council)

On June 15, 2024, an expert council was held in Moscow on the topic: «The Place of Topical Combined Multicomponent Drugs in the Treatment of Complicated Dermatoses.» The council became the basis for discussing the accumulated clinical and organizational problems in the field of using multicomponent drugs in algorithms for managing patients with dermatoses of combined etiology, with concomitant visceral or cutaneous comorbidity, the influence of exposome factors on the course of steroid-sensitive, potentially complicated skin diseases. The council discussed the feasibility of prescribing multicomponent drugs in patients with altered skin microbiome against the background of dermatoses, taking into account the risk factors for the addition of a secondary infection. The prerequisites for creating a modern algorithm for the use and the place of a three-component drug produced using micronization technology, containing betamethasone, gentamicin and clotrimazole, as part of the complex therapy of chronic inflammatory itchy skin diseases were discussed.

1. Foroutan F., Guyatt G., Zuk V., et al. GRADE recommendation 28: Using GRADE to assess the evidence for prognostic factors: certainty of assessment in identifying groups of patients with different absolute risks J Clin Epidemiol, 121 (2020), pp. 62–70.

2. Zhiltsova E. E., Politov S. A., Bakovetskaya O. V. Clinical features and tactics of therapy of comorbid dermatoses. Medical Council.– 2022.– 16 (13), 54–58. (In Russ.).

3. Conic R. Z., Miller R., Piliang M., Bergfeld W., Mesinkovska N. A. Comorbidities in patients with alopecia areata, Journal of the American Academy of Dermatology, 2017.-Volume 76, Issue 4, P. 755–757, ISSN 0190–9622

4. Davis DM, Drucker AM, Alihan A, Berkovich L, Cohen DE, Darr JM, Eichenfield LF, Fraser-Green L, Paller AS, Silverberg JI, Singh AM, Sidbury RR. American Academy of Dermatology Guidelines: Awareness of Comorbidities Associated with Atopic Dermatitis in Adults. J Am Acad Dermatol. June 2022; 86(6):1335–1336.e18. DOI: 10.1016/j.jaad.2022.01.009.

5. Andersen Y. M.F., Egeberg A., Gislason G. H., Skov L., Thyssen J. P. Burden of respiratory comorbidities in patients with atopic dermatitis and psoriasis Br J Dermatol, 177 (2017), pp. e145–e146

6. Pander K, Ghamrawi RI, Heron SE, Feldman SR. Controversial cardiovascular and hematologic comorbidities in atopic dermatitis. Arch Dermatol Res. 2022 May; 314(4):317–324. DOI: 10.1007/S00403–021–02240-Z

7. Silverberg J., Garg N., Paller A., Fishbein A., Zee P. Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Population-Based Study. Journal of Investigative Dermatology (2015) 135, 56–66; doi:10.1038/jid.2014.325

8. Qureshi А, Friedman А. Comorbidities in Dermatology: What’s Real and What’s Not. Dermatol Clin 37 (2019) 65-71.

9. Tlish M. M., Kuznetsova T. G., Naatyzh Zh. Yu., Nesterenko I. A. Comorbid pathology: mutual aggravation and difficulties of therapy. Clinical dermatology and venereology. 2022; 21(5):599–605. (In Russ.).

10. Hanifin JM, Reed ML, Eczema P et al. A population-based survey of eczema prevalence in the United States. Dermatitis.-2007.– 18:82–91.

11. Andersen Y., Egeberg A., Gislason G., Skov L., Tissena J. Autoimmune diseases in adults with atopic dermatitis J Am Acad Dermatol, 76 (2017), p. 274–280.

12. Zhang A., Silverberg J. Association of atopic dermatitis with overweight and obesity: a systematic review and meta-analysis. J Am Acad Dermatol, 72 (2015), p.606–616.

13. Kubanov A. A., Namazova-Baranova L.S., Khaitov R. M., Ilyina N. I., Alekseeva A. A., Ambarchyan E. T., Artemyeva S. I., Arshinsky M. I., Astafieva N. G., Vishneva E. A., Volnukhin V. A., Danilycheva I. V., Elisyutina O. G., Epishev R. V., Zhestkov A. V., Zhilova M. B., Zhukova O. V., Zaslavsky D. V., Znamenskaya L. F., Karamova A. E. and others. Atopic dermatitis. Russian allergological journal. 2021. T. 18. No. 3. P. 44–92. (In Russ.).

14. Kungurov N. V., Kokhan M. M., Keniksfest Yu.V., Kashcheyeva Ya.V., Letaeva O. V., Kuklin I. A., Stukova E. I. Innovative combined external agent in the therapy of complicated dermatoses: experience of use. Attending physician.-2019.– (5), 38. (In Russ.).

15. Lvov A. N. Propaedeutic principles of combined external therapy for dermatoses of combined etiology. Clinical dermatology and venereology. 2016;15(1):78–84. (In Russ.).

16. Smolkin Yu.S., Balabolkin I. I., Gorlanov I. A., Kruglova L. S., Kudryavtseva A. V., Meshkova R. Ya., Migacheva N. B., Khakimova R. F., Cheburkin A. A., Kuropatnikova E. A., Lyan N. A., Maksimova A. V., Masalsky S. S., Smolkina O. Yu. ADAIR Consensus Document: Atopic Dermatitis in Children – Update 2019 (Short Version) Part 1. Allergology and Immunology in Pediatrics. 2020. No. 1 (60). pp. 4–25. (In Russ.).

17. General characteristics of the drug Akriderm GK. Corresponds to Expert Report dated 21.11.2023 No. 24451 (sequence 0005) (In Russ.).

18. Miedzobrodzki J., Kaszycki P., Bialecka A. et al. Proteolytic activity of Staphylococcus aureus strains isolated from the colonized skin of patients with acute-phase atopic dermatitis. Eur J Clin Microbiol Infect Dis 2002; 21:269–276.

19. Kotrekhova L. P. Diagnostics and rational therapy of dermatoses of combined etiology. Consilium Medicum (supplement «Dermatology») 2010; 4: 6–11. (In Russ.).

20. Khlebnikova A. N., Marycheva N. V. Features of external therapy of skin pathology in patients with diabetes mellitus. Clinical dermatology and venereology. 2011; 6: 49–55. (In Russ.).

21. Khardikova S. A. Efficiency and tolerability of various forms of Akriderm GK in the daily practice of a dermatovenerologist. Clinical dermatology and venereology. 2016; 15 (5): 55–61. (In Russ.).

22. Lysenko O. V., Lukyanchikova L. V., Podshivalova T. V. Use of tilorone in the treatment of microbial eczema associated with trophic ulcers. Clinical dermatology and venereology. 2010;8(2):85–89. (In Russ.).